Topic Archives: Breast Cancer

Comments

  • Avatar

    20 years of Mamogram radiation causes breast cancer. the false positives leading to unecessary "treatment" are even wors...

  • Avatar

    Mike......interesting. I, too, am a recent member of Black Optics; actually, his Nucleus program. So, today, first tra...

  • Avatar

    Joinhttps://www.cytodyn.com/media/press-releases/detail/296/cytodyn-files-ind-and-protocol-for-phase-1b2-clinical the di...

  • Avatar

    Outstanding review. Another interesting potential therapy involves the CCR5 receptor on T-cells. This receptor function...

  • Avatar

    SAN DIEGO, Oct. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of ...

  • Avatar

    CytoDyn Announces Plan to Develop PRO 140 for Metastatic Triple-Negative Breast Cancer as Initial Oncology Indication. h...

  • Avatar

    My Daughter fought and lost her battle with Breast Cancer and the Braca-2 gene! She was diagnosed as triple negative.. ...

  • Avatar

    InMed CEO Eric Adams reveals info about their work with breast cancer on an interview with James West / MidasLetter, Apr...

  • Avatar

    I don't see this as Hyasynth as they are a private complamy not traded. All the clues leed to InMed Pharma. A look at so...

  • Avatar

    Appears to be INMED. My only concern is their website and last press release in May 2018 doesn't mention anything about ...

  • Avatar

    https://www.angelnexus.com/o/web/165728 Hello, did anyone notice that the above company is pumping In Med Pharmaceuti...

  • Avatar

    Medical Marijuana As A Potential Breast Cancer Treatment ... darkwebnews.com/drugs/medical-marijuana-potential-breast-c...

  • Avatar

    Just using google I ran into this: Zelda Therapeutics a medical cannabis biotechnology company has revealed medical mari...

  • Avatar

    If this is Mengels latest on the cure for breast cancer I can't figure it out either. Can't imagine something as newswo...

  • Avatar

    Does anyone know the ticker for the $1 stock that cures breast cancer?...

  • Avatar

    The C word terrifies us all. I'm sorry you had that experience. I think the cold reality is that all diseases affect ea...

  • Avatar

    Being a Breast Cancer Survivor,(early stage HR/PR Positive) I find this information concerning. Underwent a Lumpectomy, ...

  • Gr8Full!

    #X-Cancer #TILs > Immune recognition of somatic mutations leading to complete durable regression in metastatic breast ca...

  • Avatar

    I am a firm believer in the value of the Primary Care Physician to the overall health care "system" (ironic laugh here)....

  • Avatar

    I believe that breast cancer treatment is going into Phase III. In the presentation they mention various milestone pay...

  • Avatar

    Took a position in $ONCYF today which is favorably viewed by KSS and Helen and Twitter. They have an upcoming presen...

  • Avatar

    Hi Porgie. I owned $SNDX for a while as well but sold out once I took another look at the phase 2 data for E2112 - HR+, ...

  • Gr8Full!

    $OMCYF - Oncolytics Biotech(R) to Present REOLYSIN(R) at the 2018 Precision: Breast Cancer World R&D Summit 20180306 ...

  • Avatar

    Does anyone know the name of the company that has just successfully developed a cancer vaccine specifically for breast c...

  • Gr8Full!

    $ONCYF np - 20180207; Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breas...

  • Avatar

    $CASC $SGEN “Seattle Genetics disappoints Puma bulls with Cascadian takeout” Date January 31, 2018 Why buy Pu...

  • Avatar

    ONCYF- NP as of yet. Data with Reolysin doubling the survival rate for metastatic breast cancer is off the chart good. ...

  • Avatar

    I missed this post earlier, but it is indeed Patriot One. The identity of the company was cracked the day the tease was...

  • Avatar

    Syndax Pharmaceuticals Is In For A Potentially Transformative 2018 Jan.25.18 | About: Syndax Pharmaceuticals, (SNDX) ...

  • Avatar

    $ONCS - long I still own ONCS. I'm very interested in hearing more of the bear argument. In truth, I'm low on portfo...

  • Avatar

    $liquidBiopsy $BIOC $AI $MachineLearning $NVDA “CancerSEEK: Blood Test That Detects Eight Common Cancers” Ale...

  • Avatar

    $ONCS, long. OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study OncoS...

  • Avatar

    $HALO I reference the following extract from BioPharma Dive Sept. 14, 2017 titled Bristol, Roche tap Halozyme for tech p...

  • Avatar

    My wife was considering HRT 15 - 20 years ago but was scared off by the reported results of increased risk of breast can...

  • Avatar

    $RDUS NP J.P. Morgan note. “The presentation focused on the company’s commercial asset, Tymlos, which launc...

  • Avatar

    I also agree with Myron's comments. I was diagnosed with breast cancer in 2016 and sought out natural treatment. I refus...

  • Avatar

    $SNDX NP Syndax initiated with a Buy at B. Riley FBR B. Riley FBR analyst Madhu Kumar started Syndax Pharmaceutical...

  • Avatar

    $SNDX small position. Calendar says $SNDX Syndax Breast Cancer Ph3 PFS data "1H '18" So, if data is good sometime in...

  • Avatar

    $ONCS np; vs. $ONCYF np. Dr. KSS, both of these SanDiego based companies indicate their product turns cold tumors hot t...

  • Avatar

    $ONCS (long, ow) https://ir.oncosec.com/press-releases/detail/1931/oncosec-provides-2018-business-outlook OncoSec ...

  • Avatar

    $ ONCS LONG 03-Jan-2018:08:00:00, OncoSec Provides 2018 Business OutlookComplete stage 1 enrollment of PISCES/KEYNO...

  • Avatar

    kirzli, sndx-I share your concern, but I hope that entinostat will have better results with advanced hormone receptor po...

  • Avatar

    $FreeCME HER2-Positive Breast Cancer Since we discuss this often on here, this is a link for any healthcare profession...

  • Dr. KSS MD PhD

    I agree 100 percent. $SNDX shares have been sucked into the general vague biotech downdraft of recent weeks and saw some...

  • Avatar

    $SNDX This is a stock that has been puzzling me. I just keeps dropping. Their Phase 3 trial of Entinostat plus Aromac...

  • Avatar

    Thank you Doc for another excellent well reasoned and laid out article. Yes, I agree with you - I have at least one pati...

  • Avatar

    $BIOC, $SNDX long Thanks for the Syndax suggestion. I have been watching and unsure if I should nibble as well. I did...

  • Avatar

    $ONCS LONG Dr. Alain Algazi will present the updated data in an oral poster presentation (P524) at the Society for I...

  • Avatar

    $ONCS I am so impressed how this wonderful investing group works. Within a few hours after our lead scientist (DR. K...

  • Dr. KSS MD PhD

    First, bear in mind the space has much to prove. HDACi's haven't exactly blazed a path yet. I regard entinostat as being...

  • Avatar

    NP $ RDUS Radius Health announces that the FDA has granted Fast Track designation for elacestrant; (34.61) El...

  • Avatar

    Long $CLRB ll.com: Cellectar Biosciences receives additional Japanese patent for CLR 131, CLR 125 Cellectar Bioscie...

  • Avatar

    genetic tests for cancer are also available--free!--to survivers with a nasty family history of breast cancer, which cov...

  • Avatar

    $NVS It's as simple as a selfie and a hashtag on Twitter to raise money for metastatic breast cancer. Novartis don...

  • Avatar

    $SNDX Syndax - Subscriber Eemajin asked me an interesting question about $SNDX catalysts on the Gummie Catalyst Calendar...

  • Avatar

    $double post I'm happy to have read it twice Nocitons. While I'm here, I'd love to know if you, Doc, saw the Venb...

  • Dr. KSS MD PhD

    Hi....I tend to agree with you. For home gamers, CASC is the former OncoThyreon, and tucatinib inhibits the tyrosine kin...

  • Avatar

    Alley A Snickers would do it !! Look at all the other benefits of MetFormin. My wife as a breast cancer survivor got on ...

  • Avatar

    I met with MYGN a few years ago while the stock was still on the southbound express. Their super success story test (pr...

  • Dr. KSS MD PhD

    To round out linling's post, the PT of $29 is essentially a tripling of where shares of $SNDX sit now. I acquired my ove...

  • Avatar

    $SNDX Interesting the analyst didn't even mention the Phase 3 breast CA (which is somewhat behind schedule) ECOG-ACR...

  • Dr. KSS MD PhD

    PARPi olaparib boosts PFS in germline-BRCA mutational breast cancer. http://www.nejm.org/doi/full/10.1056/NEJMoa1706450...

  • Avatar

    Hi all - I just want to quickly share a personal story that shows a side of "big pharma" you most likely will never hea...

  • Avatar

    $Stem Cell Therapy - Novel Approach A stem cell-based method created by University of California, Irvine scientists c...

  • Avatar

    I will move this catalyst for $SNDX Breast Cancer program from October to December and indicate the two possible dates. ...

  • Avatar

    In any case Jab, $SNDX has several shots on goal with its 3 study Immuno-Oncology program and the FDA Breakthrough Ther...

  • Avatar

    The October Breast Cancer Entinostat HR event for Syndax is from the FDA's Biopharmcatalyst.com which has this with a No...

  • Avatar

    $SNDX- Yes this is 2 separate data readouts. SNDX's Entinostat has a breast cancer trial going on as well as an Imunoonc...

  • SoGiAm

    $BIOC long - Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy ...

  • Avatar

    Good listen on emerging data for breast cancer treatment in the future. http://noveltargets.com/category/season-3/ Che...

  • Avatar

    Wow, Doc, anything to help Inflammatory Breast Cancer would be fantastic news. My wife is six years on from her diagnos...

  • Dr. KSS MD PhD

    One wonders if ABX464 linked to the CLRB compound could have a role in inflammatory breast cancer, which is a dreaded ho...

  • Dr. KSS MD PhD

    A colleague, an Asian Indian female (and yes males do get breast cancer on occasion), lived 15 years with stage IV disea...

  • Avatar

    Thank you for your detailed explanation (I'd give two thumbs up if I could) of why you doubt efficacy in the human trial...

  • Avatar

    Wendy, She has been on meds for MS for over 20 years. These included betaseron, copaxone for many years, and tysabri f...

  • Avatar

    My best to you and your wife also. Last October my wife was diagnosed with triple negative breast cancer that was very u...

  • Avatar

    Astrazeneca's olaparib looks like the real deal for BRCA-mutated breast cancer. http://www.medscape.com/viewarticle/881...

  • Avatar

    $RDUS Long I am long on RDUS for its osteoporosis drug abaloparatide-SC. It's gotten FDA approval and is currently ...

  • Avatar

    Essiac is A cure for breast cancer nurse Rene M. Caisse ,was persecuted for helping cure paitionts with it.To get the or...

  • Avatar

    $RDUS Long : Hello Doc and fellow gummies, Since the tymlos approval and amgen safety issues, the stock has had extreme...

  • Avatar

    $IMMU A post from 2014 by Dr. KSS had somewhat positive things to say about Immunomedics. Their drug for triple negative...

  • Avatar

    $SNDX The enrollment and release of interim data for their Phase 3 in breast cancer is behind schedule. "Based on ...

  • Avatar

    I belong to a group of fans that reads and suggests changes to novels of Mark Dawson, a British writer of 007 type ficti...

  • Avatar

    Dr., I have a very basic question that perhaps you could spend a few minutes on during the call if you think it would be...

  • Avatar

    $RDUS np Thanks for the reminder. I've been in and out of RDUS since Glenn & Doc first brought it to our attention....

  • Dr. KSS MD PhD

    Interesting points, but it's not clear to me that PPAR gamma agonism would support elaboration of breast cancer. I'm not...

  • Avatar

    $Coffee Ralph: Thanks so much for a great reading list! I promptly launched into a search for practical ways to remov...

  • Avatar

    $VBLT Long VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target TEL AVIV, Israel, April 04,...

  • SoGiAm

    $VBLT long - VBL Therapeutics has added a news release to its Investor Relations website. http://ir.vblrx.com/phoenix.z...

  • Avatar

    $SNDX: Syndax announces 5 poster presentations at AACR17 (Washington, D.C., April 1-4) Key Entinostat Posters of ...

  • Avatar

    $TSRO: Jeff, congrats. You should thank yourself for a smart decision, not me. I am currently out of the shares, but...

  • Avatar

    $SNDX long This was one of the 12 Biotechs of Xmas. In Doc's original write up, I believe at that time they expected so...

  • Avatar

    $ no-ticker Researchers believe they have found the key to drug resistance in most common type of breast cancer htt...

  • Avatar

    Novartis gets quick FDA nod with LEE011 for breast cancer. https://endpts.com/watch-out-pfizer-novartis-lee011-bags-q...

  • Avatar

    PARP Inhibitors bring hope to breast cancer patients.(Target cancer cells only and well tolerated) https://www.firstwor...

  • Avatar

    $AKAO, AUPH, PTLA, SNDX and VBLT long all. It always helps me when I read what others are doing/thinking, so I thought I...

  • Avatar

    $SNDX long Thanks for link Ben. The Phase 3 for breast cancer is slated 2h17. On their last call, I think they alluded ...

  • Avatar

    $SNDX, no position. I'm woefully behind on the threads and my own independent due diligence because I've started a new...

  • Avatar

    Tim, My mom survived breast cancer and my dad prostate cancer, so I can empathize. Surround yourself with as much famil...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch